Literature DB >> 14528304

Enhancement of CIITA transcriptional function by ubiquitin.

Susanna F Greer1, Eleni Zika, Brian Conti, Xin-Sheng Zhu, Jenny P-Y Ting.   

Abstract

Although increasing evidence indicates that there is a direct link between ubiquitination and mono-ubiquitination and transcription in yeast, this link has not been demonstrated in higher eukaryotes. Here we show that the major histocompatibility complex (MHC) class II transactivator (CIITA), which is required for expression of genes encoding MHC class II molecules, is ubiquitinated. This ubiquitination enhanced the association of CIITA with both MHC class II transcription factors and the MHC class II promoter, resulting in an increase in transactivation function and in the expression of MHC class II mRNA. The degree of CIITA ubiquitination was controlled by histone acetylases (HATs) and deacetylases (HDACs), indicating that the crucial cellular processes mediated by these enzymes are linked to regulate transcription. Thus, ubiquitin positively regulates a mammalian coactivator by enhancing its assembly at the promoter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528304     DOI: 10.1038/ni985

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  41 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

Review 2.  Ubiquitin and proteasomes in transcription.

Authors:  Fuqiang Geng; Sabine Wenzel; William P Tansey
Journal:  Annu Rev Biochem       Date:  2012-03-08       Impact factor: 23.643

Review 3.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

4.  Regulation of LIM-domain-binding 1 protein expression by ubiquitination of Lys134.

Authors:  Paul W Howard; Shall F Jue; David G Ransom; Richard A Maurer
Journal:  Biochem J       Date:  2010-07-01       Impact factor: 3.857

5.  The role of the proteasomal ATPases and activator monoubiquitylation in regulating Gal4 binding to promoters.

Authors:  Anwarul Ferdous; Devanjan Sikder; Thomas Gillette; Kip Nalley; Thomas Kodadek; Stephen Albert Johnston
Journal:  Genes Dev       Date:  2006-12-13       Impact factor: 11.361

6.  Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Authors:  Giovanna Tosi; Greta Forlani; Vibeke Andresen; Marco Turci; Umberto Bertazzoni; Genoveffa Franchini; Guido Poli; Roberto S Accolla
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 7.  No Splicing, no dicing: non-proteolytic roles of the ubiquitin-proteasome system in transcription.

Authors:  Thomas Kodadek
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

8.  Non-proteolytic regulation of p53-mediated transcription through destabilization of the activator.promoter complex by the proteasomal ATPases.

Authors:  Young-Chan Kim; Shwu-Yuan Wu; Hyun-Suk Lim; Cheng-Ming Chiang; Thomas Kodadek
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

Review 9.  The 'ubiquitous' reality of vector immunology.

Authors:  Maiara S Severo; Olivia S Sakhon; Anthony Choy; Kimberly D Stephens; Joao H F Pedra
Journal:  Cell Microbiol       Date:  2013-03-14       Impact factor: 3.715

10.  Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.

Authors:  Olivia I Koues; R Kyle Dudley; Agnieszka D Truax; Dawson Gerhardt; Kavita P Bhat; Sam McNeal; Susanna F Greer
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.